Atrium Therapeutics, Inc.
RNA
$12.69
$0.373.00%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -71.11% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -71.11% | ||||
| Cost of Revenue | 90.03% | ||||
| Gross Profit | -195.40% | ||||
| SG&A Expenses | 819.24% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 224.82% | ||||
| Operating Income | -365.56% | ||||
| Income Before Tax | -365.86% | ||||
| Income Tax Expenses | -99.35% | ||||
| Earnings from Continuing Operations | -153.09% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -153.09% | ||||
| EBIT | -365.56% | ||||
| EBITDA | -367.95% | ||||
| EPS Basic | -- | ||||
| Normalized Basic EPS | -- | ||||
| EPS Diluted | -- | ||||
| Normalized Diluted EPS | -- | ||||
| Average Basic Shares Outstanding | -- | ||||
| Average Diluted Shares Outstanding | -- | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||